SABS — SAB Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $258.40m
- $158.97m
SAB Biotherapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: Sab Biotherapeutics Announces Q1 2024 Financial Results
SAB Biotherapeutics Inc expected to post a loss of 96 cents a share - Earnings Preview
Brief: Sab Biotherapeutics Appoints Jay Skyler, MD, To The Board Of Directors
Brief: Sab Biotherapeutics On April 12, Completed Dosing Of Cohort 3 For Phase One Trials Of Sab-142
SAB Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Sab Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center To Advance Potential Influenza Treatment
Brief: SAB Biotherapeutics Announces Executive Leadership Change
Brief: Sab Biotherapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: SAB Biotherapeutics Announces 1-For-10 Reverse Stock Split
Brief: Sab Biotherapeutics Appoints Katie Ellias To The Board Of Directors
Brief: SAB Biotherapeutics Appoints Michael G. King Jr. As Chief Financial Officer
Brief: SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, Potential Treatment for Type 1 Diabetes
Brief: Sab Biotherapeutics Announces Private Placement Of Up To $130 Million
SAB Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes At FORCIS 2023
SAB Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary